Abstract for AD/PD™ 2026 Alzheimer’s & Parkinson’s Diseases Conference – March 17-21, 2026 News & EventsBy March 17-21, 2026
Parkinson’s Disease: Professor David Devos Honored by the French National Academy of Medicine Press ReleasesBy December 18, 2025
International Parkinson and Movement Disorder Society 2025 – InBrainPharma Presentation News & EventsBy October 9, 2025
International Parkinson and Movement Disorder Society 2025 – InBrainPharma Poster News & EventsBy October 8, 2025
InBrain Pharma to Present Long-Term Follow-Up Clinical Data from Its Phase I/II DIVE-I Trial in Parkinson’s Disease at the MDS 2025 Conference Press ReleasesBy September 22, 2025
France Parkinson takes a stake in InBrain Pharma, a company developing A-dopamine therapy for brain infusion Press ReleasesBy July 22, 2025
InBrain Pharma receives EMA Positive Scientific Advice supporting Phase 3 clinical development of A-dopamine for the treatment of advanced Parkinson’s disease Press ReleasesBy July 3rd, 2025
InBrain Pharma Secures €1.8 Million in Funding for the PERCEPAR Project under France 2030’s “First Factory” Initiative to Industrialize Anaerobic Dopamine Production for Parkinson’s Disease Press ReleasesBy May 12, 2025
A World Premiere in Parkinson’s Disease With significant clinical results published in the Nature Medicine Journal, InBrain Pharma is about to durably modify the advanced Parkinson’s disease management Press ReleasesBy January 27, 2025
InBrain Pharma to Present Positive Results from Its DIVE-I Phase I/II Clinical Trial for Parkinson’s Disease at the Congress of Parkinson’s Disease and Movement Disorders from September 27 to October 1 in Philadelphia Press ReleasesBy September 25, 2024
